Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02749214 |
|
Recruitment Status :
Recruiting
First Posted : April 22, 2016
Last Update Posted : October 27, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to determine the potential for a Parkinson's Disease (PD) -specific breath signature as a non-invasive screening tool for identifying PD patients with inflammation, tracking the progression of disease, and responsiveness to various therapeutic interventions, in particular anti-inflammatory or immunomodulatory therapies. Neurological disorders include any disorder involving the brain or the nervous system, for example memory disorders, stroke, movement disorders and many other conditions.
The study will lay the foundation for future studies in which breath fingerprinting could be used as a screening technique. Investigators will also be looking at how the breath fingerprint correlates with inflammatory proteins in the blood.
| Condition or disease | Intervention/treatment |
|---|---|
| Parkinson's Disease | Other: Blood Sample Collection Other: Breath Sample Collection |
The purpose of this study is to determine the potential for a Parkinson's Disease (PD) -specific breath signature as a non-invasive screening tool for identifying PD patients with inflammation, tracking the progression of disease, and responsiveness to various therapeutic interventions, in particular anti-inflammatory or immunomodulatory therapies. Neurological disorders include any disorder involving the brain or the nervous system, for example memory disorders, stroke, movement disorders and many other conditions.
The study will lay the foundation for future studies in which breath fingerprinting could be used as a screening technique. Investigators will also be looking at how the breath fingerprint correlates with inflammatory proteins in the blood.
Investigators will determine how molecules in human breath can define a "breath signature" that can be associated with neurological disorders like Parkinson's disease. The long-term goal of this study is to use blood inflammatory marker relationships and Breath Analytical Approach to identify individuals at risk for development of neurologic disorders and to monitor the effects of immune interventions on the rate of disease progression.
The study team will recruit a total of 100 participants: 50 early stage (defined by a Hohn & Yahr Stages 1-2), non-smoking Parkinson's Disease patients from among the Emory Movement Disorders Clinic and 50 age and sex-matched healthy controls (HC). Investigators will recruit six to eight participants per month over an 18-month time period.
| Study Type : | Observational |
| Estimated Enrollment : | 100 participants |
| Observational Model: | Case-Control |
| Time Perspective: | Prospective |
| Official Title: | Defining a Parkinson's Disease (PD) -Specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes |
| Study Start Date : | February 2016 |
| Estimated Primary Completion Date : | August 2018 |
| Estimated Study Completion Date : | August 2018 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
Parkinson's Disease (PD)
Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
|
Other: Blood Sample Collection
Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers. Other: Breath Sample Collection Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath. |
|
Healthy Control
Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
|
Other: Blood Sample Collection
Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers. Other: Breath Sample Collection Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath. |
- Unified Parkinson's Disease Rating Scale Subscale II Score [ Time Frame: Up to 15 minutes ]The Unified Parkinson's Disease Rating Scale Subscale II is a measure of self-evaluation of the activities of daily life (ADLs) including speech, swallowing, handwriting, dressing, hygiene, falling, salivating, turning in bed, walking, and cutting food. Items are rated from 0 (normal) to 4 (severe). A higher total score indicates more severe disease.
- Unified Parkinson's Disease Rating Scale Subscale III Score [ Time Frame: Up to 15 minutes ]The Unified Parkinson's Disease Rating Scale Subscale III is a clinician-scored monitored motor evaluation. Items are rated from 0 (normal) to 4 (severe). A higher total score indicates more severe disease.
- Modified Hoehn and Yahr Scale Score [ Time Frame: Up to 15 minutes ]The Modified Hoehn and Yahr Scale is used to describe how the symptoms of Parkinson's disease progress. Stages of disease range from 1 to 5 where 5 is the most severe.
- Overnight Questionnaire Score [ Time Frame: Up to 15 minutes ]The Overnight Questionnaire is completed by a person living with the participant with Parkinson's Disease. Questions refer to behaviors witnessed during sleep. Questions are answered on a scale from 1 (never) to 4 (always). A higher score indicates more symptoms of sleep disruption.
- Beck's Depression Scale Score [ Time Frame: Up to 15 minutes ]The Beck's Depression Scale is a 21 one item scale used to describe how a participant has been feeling over the past two weeks. A total score between 0-21 indicates very low anxiety. A between 22-35 indicates moderate anxiety. A score that exceeds 36 indicates high anxiety.
- Montreal Cognitive Assessment (MOCA) Score [ Time Frame: Up to 10 minutes ]The Montreal Cognitive Assessment (MOCA) is a rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The total possible score is 30 points; a score of 26 or above is considered normal.
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Participants with Parkinson's Disease (PD)
Inclusion Criteria:
- Must be capable of providing written informed consent
- Non-smoking
- Clinical diagnosis of PD Hohn & Yahr Stages 1 and 2
Exclusion Criteria:
- Cognitively impaired to the degree that they are not able to provide consent
Healthy Controls
Inclusion Criteria:
- Must be capable of providing written informed consent
- Age matched and a family member or healthy community control
Exclusion Criteria:
- Diagnosed with cancer and/or undergoing cancer treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02749214
| Contact: Malu Tansey, PhD | 404-727-6126 | malu.tansey@emory.edu | |
| Contact: Elaine F Sperin | 404-712-7044 | esperin@emory.edu |
| United States, Georgia | |
| The Emory Clinic Executive Park | Recruiting |
| Atlanta, Georgia, United States, 30329 | |
| Contact: Malu Tansey, PhD 404-727-6126 malu.tansey@emory.edu | |
| Principal Investigator: | Malu Tansey, PhD | Emory University | |
| Principal Investigator: | Charlene W Bayer, PhD | Hygieia, Inc |
| Responsible Party: | Malu Tansey, Associate Professor, Emory University |
| ClinicalTrials.gov Identifier: | NCT02749214 History of Changes |
| Other Study ID Numbers: |
IRB00086732 |
| First Posted: | April 22, 2016 Key Record Dates |
| Last Update Posted: | October 27, 2017 |
| Last Verified: | October 2017 |
Additional relevant MeSH terms:
|
Parkinson Disease Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Movement Disorders Neurodegenerative Diseases |